Spyre Therapeutics, Inc.
SYRE
Peringkat dalam Saham
#2339
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Harga Saham
$91.87
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$8.48B
Perubahan (1 hari)
8.44%
Perubahan (1 tahun)
295.14%
Negara
US
Perdagangan Spyre Therapeutics, Inc. (SYRE)
Kategori
Healthcare
Jumlah saham beredar untuk Spyre Therapeutics, Inc. (SYRE)
Jumlah saham beredar per June 2026: 84.73M
Menurut laporan keuangan terbaru dan harga saham Spyre Therapeutics, Inc., jumlah saham beredar saat ini adalah 84.73M. Pada akhir December 2023, perusahaan memiliki 6.90M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Spyre Therapeutics, Inc. (SYRE) dari 2014 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 84.73M | 80.17% |
| 2024 | 47.03M | 581.85% |
| 2023 | 6.90M | 104.59% |
| 2022 | 3.37M | 28.19% |
| 2021 | 2.63M | 23.18% |
| 2020 | 2.13M | 67.05% |
| 2019 | 1.28M | 53.44% |
| 2018 | 832.90K | 37.64% |
| 2017 | 605.13K | 54.50% |
| 2016 | 391.67K | -14.33% |
| 2015 | 457.19K | -16.45% |
| 2014 | 547.19K | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | 199.66% |
US
|
|
| 396.00M | 367.37% |
US
|
|
| 478.91M | 465.23% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -26.61% |
NL
|
